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Editorial Comment
 This report by Dalpiaz and cols. is strikingly important. They present a 35 month follow-up of male 
patients with SUI who underwent Argus sling placement. Their data point out an unacceptably high rate of 
complications (83%) of which more than half (58%) were grade 3 according to the Clavien system. Seventy-
two percent of patients referred dissatisfaction with treatment. Only 17% remained dry, although 79% of 
subjects were dry when discharged home after the procedure, which shows the non sustainable efficacy of the 
device.
 Ninety three percent of the studied population was classified as having a moderate / severe inconti-
nence according to the number of pads used which may have influenced the low success rate. But the high 
complication rate obviates a need to review not only the device but the surgical technique for implantation 
itself.
 Other reports on the Argus system are encouraged in order to corroborate these findings, but a red flag 
must be raised.
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Background: The authors tested the performance of the currently used clinical criteria reported in populations 
studied by van den Bergh et al. and Carter et al. for the selection of patients with prostate cancer (PCa) for 
active surveillance (AS) according to age.
Methods: Data were analyzed from 893 patients who underwent with radical prostatectomy (RP). The authors 
investigated the rates of unfavorable PCa at RP (extracapsular extension, seminal vesicle or lymph node inva-
sion, or Gleason score 7-10) in patients who fulfilled AS criteria according to age tertiles (ages ≤ 63 years, 
63.1 to 69 years, and > 69 years). Area under the plasma concentration time curve (AUC) analyses tested the 
criteria for predicting unfavorable PCa. Then, the patients were stratified according to the cutoff age of 70 
years. Multivariate analyses were used to test the role of age in predicting unfavorable PCa.
Results: The rate of unfavorable PCa characteristics was between 24% and 27.8%. In the van den Bergh et 
al. population, after age 70 years, the rate of unfavorable PCa characteristics was 41% compared with 23.2% 
and 24.1% in patients in the previous age tertiles (ages ≤ 63 years and 63.1 to 69 years, respectively). In the 
Carter et al. population, the rate of unfavorable PCa was 41.2% compared with 17.3% and 18.6% in the previ-
ous age tertiles (ages ≤ 63 years and 63.1 to 69 years, respectively). When the 70-year age cutoff was used, 
unfavorable PCa was identified in 17.9% to 23.6% of patients aged < 70 years versus 4% to 41.2% of patients 
aged > 70 years (all P < .001). AUC analyses revealed significantly lower performance in older patients. In 
multivariate analyses, after adjustment for prostate-specific antigen, prostate volume, and the number of cores, 
age represented an independent predictor of unfavorable PCa.
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Conclusions: The currently used AS criteria performed significantly better for patients aged < 70 years. The 
authors concluded that the current results should be taken into account when deciding whether to offer active 
surveillance to patients with low-risk PCa.
Editorial Comment
 The major issue related to an initial surveillance policy is the possibility of losing the window of cur-
ability of the disease, and this is directly related to patients’ life expectancy according to their comorbidity 
profile and disease natural history that are very heterogeneous and unpredictable, in part due to the misclas-
sification of patients regarding these variables.
 Previous studies suggest an association between age and prostate cancer aggressiveness, this study 
though retrospective and not including patients under active surveillance, highlights that older patients are 
affected more frequently by more aggressive disease at final pathology compared with their younger coun-
terparts, even when they are affected by very-low-risk disease according to the criteria proposed by van den 
Bergh et al. and Carter et al..
 In this context, mortality should be considered as the main outcome in future confirmatory studies 
and while older patients are typically encouraged to undergo active surveillance due to virtually shorter life 
expectancy, better tools predicting life expectancy and disease natural history are warranted.
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Background: Although benign prostate hyperplasia (BPH) and prostate cancer (PCa) share features such as 
hormone-dependent growth and response to treatment with antiandrogen therapy, BPH is generally not con-
sidered a premalignant lesion.
Objective: To determine whether clinical BPH is associated with an increased risk of PCa incidence and mor-
tality.
Design, Setting, and Participants: Using designs with individual participant data from five national registries, 
we studied the entire Danish male population from 1980 through 2006, a total of 3 009 258 Danish men. We 
collected PCa diagnoses (n = 53 315), information on PCa mortality (n = 25 459), and ascertained clinical 
BPH (not histologically proven BPH) through hospitalization (n = 187 591) and/or surgery (n = 77 698) from 
1980 to 2006 and the use of α-adrenergic receptor antagonists (n = 143 365) and/or the use of 5α-reductase 
inhibitors (5-ARIs) (n = 47 465) from 1995 to 2006.
